145 related articles for article (PubMed ID: 32867806)
1. A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer.
Beachler DC; Lamy FX; Russo L; Taylor DH; Dinh J; Yin R; Jamal-Allial A; Dychter S; Lanes S; Verpillat P
J Ovarian Res; 2020 Aug; 13(1):101. PubMed ID: 32867806
[TBL] [Abstract][Full Text] [Related]
2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
Lairson DR; Parikh RC; Cormier JN; Du XL
Value Health; 2014; 17(1):34-42. PubMed ID: 24438715
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
Eisenhauer EL; Sonoda Y; Levine DA; Abu-Rustum NR; Gemignani ML; Sabbatini PJ; Barakat RR; Chi DS
Am J Obstet Gynecol; 2008 Feb; 198(2):213.e1-7. PubMed ID: 18226627
[TBL] [Abstract][Full Text] [Related]
6. Development of predictive models to identify advanced-stage cancer patients in a US healthcare claims database.
Esposito DB; Russo L; Oksen D; Yin R; Desai VCA; Lyons JG; Verpillat P; Peñalvo JL; Lamy FX; Lanes S
Cancer Epidemiol; 2019 Aug; 61():30-37. PubMed ID: 31128428
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R; Kurosky SK; Udall M; Chang J; Cappelleri JC; Doherty JP; Kaye JA
Int J Gynecol Cancer; 2018 May; 28(4):738-748. PubMed ID: 29538247
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
9. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.
Westin SN; Louie-Gao M; Gupta D; Thaker PH
Future Oncol; 2021 Nov; 17(32):4263-4274. PubMed ID: 34378405
[No Abstract] [Full Text] [Related]
11. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.
Donato BM; Burns L; Willey V; Cohenuram M; Oliveria S; Yood MU
Clin Ther; 2010 Mar; 32(3):546-54. PubMed ID: 20399992
[TBL] [Abstract][Full Text] [Related]
12. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
Chang SJ; Hodeib M; Chang J; Bristow RE
Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
[TBL] [Abstract][Full Text] [Related]
13. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
14. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.
Clarke-Pearson DL; Van Le L; Iveson T; Whitney CW; Hanjani P; Kristensen G; Malfetano JH; Beckman RA; Ross GA; Lane SR; DeWitte MH; Fields SZ
J Clin Oncol; 2001 Oct; 19(19):3967-75. PubMed ID: 11579118
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel in the management of ovarian cancer.
Blagden SP; Kaye SB
Expert Rev Anticancer Ther; 2005 Apr; 5(2):203-14. PubMed ID: 15877518
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
[TBL] [Abstract][Full Text] [Related]
17. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
Caponigro F; Willemse P; Sorio R; Floquet A; van Belle S; Demol J; Tambaro R; Comandini A; Capriati A; Adank S; Wanders J
Invest New Drugs; 2005 Jan; 23(1):85-9. PubMed ID: 15528985
[TBL] [Abstract][Full Text] [Related]
19. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential.
Barakat RR; Benjamin I; Lewis JL; Saigo PE; Curtin JP; Hoskins WJ
Gynecol Oncol; 1995 Dec; 59(3):390-3. PubMed ID: 8522261
[TBL] [Abstract][Full Text] [Related]
20. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
